XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements Of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash flows from operating activities    
Net loss $ (12,994) $ (28,958)
Depreciation and amortization 895 923
Impairment loss 140 0
Movement in allowance for doubtful accounts receivable 386 514
Loss from equity-accounted investments (Note 5) (1,156) (19,137)
Movement in allowance for doubtful loans to equity-accounted investments 0 78
Fair value adjustment related to financial liabilities (90) 886
Interest payable 11 (63)
Profit on disposal of property, plant and equipment (165) (10)
Stock-based compensation charge (Note 12) 309 399
Dividends received from equity accounted investments 137 57
Decrease (Increase) in accounts receivable and finance loans receivable 1,188 (8,115)
Decrease in inventory 1,583 2,359
Decrease in accounts payable and other payables (431) (415)
Increase (Decrease) in taxes payable 294 (14,917)
Decrease in deferred taxes (367) (1,755)
Net cash used in operating activities (7,948) (29,880)
Cash flows from investing activities    
Capital expenditures (698) (275)
Proceeds from disposal of property, plant and equipment 231 16
Proceeds from disposal of Net1 Korea 0 20,114
Proceeds from disposal of DNI as equity-accounted investment 0 329
Loan to equity-accounted investment 0 78
Net change in settlement assets 0 4,068
Net cash (used in) provided by investing activities (467) 24,174
Cash flows from financing activities    
Proceeds from bank overdraft (Note 8) 138,905 69,146
Repayment of bank overdraft (Note 8) (98,908) (76,850)
Proceeds from disgorgement of shareholders' short-swing profits 0 98
Net change in settlement obligations 0 (4,068)
Net cash provided by (used in) financing activities 39,997 (11,674)
Effect of exchange rate changes on cash (4,925) 806
Net increase (decrease) in cash, cash equivalents and restricted cash 26,657 (16,574)
Cash, cash equivalents and restricted cash - beginning of period 223,765 232,485
Cash, cash equivalents and restricted cash - end of period (Note 14) $ 250,422 $ 215,911